Ex Vivo/In Vivo Platforms for Translational Oncology Research, presented by Maria Manicini, PhD, Vice President of Pharmacology

Discovering and developing oncology therapeutics requires consideration of very specific clinical and molecular characteristics within targeted patient populations, and even sub-populations. Drug development programs can be advanced more efficiently with the support of sophisticated translational research tools, such as PDX models in an ex vivo and in vivo setting.

Champions Oncology PDX models are the most highly-characterized, clinically-relevant cohorts of PDX models to optimally predict success and accelerate the drug development process.

This webinar will provide an overview of the various unique and advanced translational tools that are offered by Champions oncology in an in vivo and ex vivo setting.